PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology4 citations

Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study.

View Full Paper

Authors

AXAnwen XiongTongji UniversityXLXingYa LiFirst Affiliated Hospital of Zhengzhou UniversityNYNong YangCentral South University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xiong et al. (2024) studied this question.

synapsesocial.com/papers/68e66b2fb6db6435875f6d01https://doi.org/10.1200/jco.2024.42.16_suppl.3106
Ask AI
Helpful
Bookmark
Share
View Full Paper